WO1997005161A1 - Boronic acid derivatives - Google Patents
Boronic acid derivatives Download PDFInfo
- Publication number
- WO1997005161A1 WO1997005161A1 PCT/EP1996/003314 EP9603314W WO9705161A1 WO 1997005161 A1 WO1997005161 A1 WO 1997005161A1 EP 9603314 W EP9603314 W EP 9603314W WO 9705161 A1 WO9705161 A1 WO 9705161A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- residue
- pharmaceutically acceptable
- compounds
- Prior art date
Links
- BQEBFHXDGVCENZ-UHFFFAOYSA-N CC(C)(C(C1)CC2OC)C1C2(C)OC Chemical compound CC(C)(C(C1)CC2OC)C1C2(C)OC BQEBFHXDGVCENZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to boronic acid derivatives, a process for their production, their use as a pharmaceutical, e.g. as thrombin inhibitors, and pharmaceutical preparations containing them.
- Thrombin is a trypsin-like serine protease fulfilling a central role in both haemostasis and thrombosis.
- thrombin is the final key enzyme, proteolytically cleaving fibrinogen to release fibrinopeptides A and B and generate fibrin, which can then polymerize to form a haemostatic plug leading to occlusion of the vessels.
- the trimethylsilyl-Ala residue, the Pro residue and the N-substituted Lys residue may each have the L or D configuration.
- the Pro residue and the N-substituted Lys residue each have the L-configuration and the trimethylsilyl Ala residue the D-configuration.
- residue of formula (a) may exist in cis or trans configuration.
- Preferred residue of formula (a) is
- the present invention embraces all isomers and their mixtures.
- the compounds of formula I wherein each of Q, and Q 2 is OH may exist e.g. in free or salt form.
- Salts include acid addition salts with e.g. organic acids, polymeric acids or inorganic acids, for example hydrochloric acid.
- the compounds of formula I are in free form.
- the present invention also includes a process for the production of the compounds of formula I, which process comprises a) to produce a compound of formula I wherein Q, and Q 2 form together a residue of formula (a), formylating a compound of formula II
- R is benzyloxycarbonyl or another amino protecting group and, where required, replacing the amino protecting group R by a benzyloxycarbonyl group, or b) to produce a compound of formula I wherein each of Q. and Q 2 is OH, cleaving a compound of formula I wherein Q, and Q 2 form together a residue of formula (a), and recovering the compounds of formula I thus obtained wherein each of Q, and Q 2 is OH in free form or in salt form.
- the formylation step a) may conveniently be performed by using mixed anhydride of acetic acid and formic acid.
- the reaction may advantageously be carried out in an organic solvent, e.g. tetrahydrofuran.
- R in compound of formula II is preferably benzyloxycarbonyl.
- R is an amino protecting group other than benzyloxycarbonyl, it may be e.g. tert.-butoxycarbonyl or an amino protecting group as disclosed in "Protective Groups in Organic Synthesis", T.W. Greene, J. Wiley & Sons NY (1981), 219-287.
- R in the compounds of formula II is other than benzyloxycarbonyl, the formylation may conveniently be carried out before replacement of said protecting group R by benzyloxycarbonyl.
- the replacement of R by a benzyloxycarbonyl group may be performed in accordance widi methods known and practiced in the art.
- Process step b) may conveniently be performed by using e.g. NaIO 4 , advantageously in an organic solvent, e.g. acetone.
- Boc tert.-butoxycarbonyl
- Boc-D-TMSal-Pro-BoroLys-OPin used as starting material may be prepared as disclosed in WO 94/20526.
- the compounds of formula I or a pharmaceutically salt thereof when each of Q, and Q 2 is OH exhibit pharmacological activity and are useful as pharmaceuticals.
- the compounds of formula I show trypsin-like serine protease inhibiting properties, as indicated in the following test methods:
- Test substance is dissolved in cremophor/ethanol (1:1) or DMSO and diluted with distilled water to yield a 1 mM stock solution. Further dilutions are made into the assay buffer (100 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCI and 0.1 % bovine serum albumin). Kinetic assays are performed using a
- each well contains 50 ⁇ l substrate, 100 ⁇ l test compound and 100 ⁇ l enzyme in buffer.
- Assays are initiated by adding enzyme to solutions containing the substance to be tested and substrate.
- E, S, P, and I are the enzyme, substrate, product (p-nitroaniline) and inhibiting substance to be tested, respectively, and k on and l ⁇ are the association and dissociaton rate constants for the inhibition (Tapparelli et al.. J. Biol. Chem.,
- In vitro coagulation assays are performed with pooled citrated human plasma. Substance to be tested or solvent are incubated with plasma for 10 min at 37°C prior to assay. Thrombin time(TT) determinations are performed at a final thrombin concentration of 5 U/ml. Activated partial thromboplastin time (APTT) is determined by incubating 0.1 ml plasma ⁇ substance to be tested with 0.1 ml purified soya bean phospholipid in ellagic acid (Actin-FS) for 4 min at 37°C and followed by the addition of 0.1 ml CaCl 2 (50mM).
- Actin-FS soya bean phospholipid in ellagic acid
- compounds of formula I significantly increase TT and APTT at a concentration of from 0.1 ⁇ M to 0.5 ⁇ M.
- prolongation of TT above 300 sec is achieved at 1.0 ⁇ M
- elevation of APTT to 2x is achieved at 1.8 ⁇ M.
- the compounds of formula I prevent thrombus formation in a dose dependent manner.
- thrombus formation is inhibited by 50 % at a dose ( ED JO ) of 0.96 mg/kg i.v. and at a dose of 15.9 mg/kg p.o.
- the compound of Example 2 has an ED 50 of 0.43 mg/kg i.v.
- the compounds of Examples 1 and 2 showed an oral effect bioavailability of 35% and 11%, respectively, in conscious aortic catheter rats.
- the compounds of Ex. 1 and 2 are also administered i.v. and p.o. to the same animals, the oral effect bioavailability is > 15% for both compounds.
- the method is a modification of that disclosed by Clozel et al. in J. Cardiovasc. Pharmacol., 12, 520-525, 1988.
- Male wistar rats are anaesthetized and the right jugular vein and the left carotid artery are exposed and cannulated .
- the cotton thread containing silicone tubing is inserted between ti e vein and the artery. Animals are pretreated with the compound to be tested via the jugular vein 20 min prior to
- Clot lysis is induced via the carotid artery by a bolus injection of t-PA followed by a 30 min infusion. Clot dissolution is monitored by placing a Nal crystal scintillation detector over the clot containing chamber. In this assay, the compound of Ex. 1 does not affect t-PA induced clot lysis and the compound of Ex. 2 even enhances clot lysis at a dose of 60 ⁇ g/kg/min.
- the compounds of formula I are therefore useful for preventing or treating thrombosis, for example deep vein thrombosis, pulmonary embolism, in peri-operative antithrombotic cover, arterial thrombosis, unstable angina, disseminated intravascular coagulation (DIC), e.g. induced by sepsis trauma or certain cancers, coronary artery bypass surgery, for the control of coagulation and fibrinolysis, for inhibiting vascular remodelling (proliferation, migration of smooth muscle cells) following venous or arterial surgery or other forms of vascular injuries, e.g. percutaneous transluminal coronary angioplasty, allo- or xenotransplantation surgery, transplant vasculopathies, graft vessel diseases, acute or chronic restenosis and obstructive vascular atherosclerosis, .
- thrombosis for example deep vein thrombosis, pulmonary embolism, in peri-operative antithrombotic cover, arterial thrombosis, unstable angina, dissemin
- the required dosage will of course vary depending on the mode of administration, the particular condition to be treated and the effect desired. In general, however, satisfactory results are achieved at dosage rates of from about 0.01 to 15 mg/kg animal body weight. Suitable daily dosage rates for larger mammals, for example humans, are of the order of from about 1 to 750 mg/day, conveniently administered once, in divided dosages 2 to 4 x / day, or in sustained release form.
- Suitable daily dosage rates for larger mammals, for example humans are of the order of from about 1 to 750 mg/day, conveniently administered once, in divided dosages 2 to 4 x / day, or in sustained release form.
- Compounds of formula I wherein each of Q, and Q 2 is OH may be administered in free form or in pharmaceutically acceptable salt form. Such salts may be prepared in conventional manner and exhibit the same order of activity as the free compounds.
- the present invention also provides a pharmaceutical composition comprising a compound of formula I, in free base form or in pharmaceutically acceptable salt form when each of Q, and Q 2 is OH, in association with a pharmaceutically acceptable diluent or carrier. Such compositions may be formulated in conventional manner.
- Compounds of formula I may be administered by any conventional route, for example in particular enterally, preferably orally, e.g. in the form of tablets, capsules or drink solutions, or parenterally e.g. in form of injectable solutions or suspensions.
- the present invention further provides: a) a compound of formula I or a pharmaceutically acceptable salt thereof when each of Q, and Q 2 is OH, for use as a pharmaceutical;
- the compounds of the invention may be employed as adjunct or adjuvant to other therapy, e.g. a therapy employing an anti-thrombotic agent, a fibrinolytic agent or an immunomodulatory agent, e.g. aspirin, heparin, t-PA, streptokinase, cyclosporins, ascomycins, brequinar, leflunomide or rapamycin or an analog thereof, azathioprine, methotrexate, mizoribine, mycophenolic acid or mycophenolate mofetil.
- a therapy employing an anti-thrombotic agent, a fibrinolytic agent or an immunomodulatory agent, e.g. aspirin, heparin, t-PA, streptokinase, cyclosporins, ascomycins, brequinar, leflunomide or rapamycin or an analog thereof, azathioprine, methotrexate, mizoribine, mycophenolic acid or my
- a method for preventing or treating disorders as indicated above in a subject in need of such a treatment comprises administering to said subject an effec ⁇ tive amount of i) a compound of the invention and ii) a second drug substance, said second drug substance being a therapeutic agent as indicated above; and
- the compounds of formula I particularly the compound of Example 2, have an interesting pharmacological profile, e.g. as disclosed above, as they exhibit an improved selectivity for thrombin and trypsin and a good oral bioavailability.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67379/96A AU6737996A (en) | 1995-07-28 | 1996-07-26 | Boronic acid derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9515489.4 | 1995-07-28 | ||
GBGB9515489.4A GB9515489D0 (en) | 1995-07-28 | 1995-07-28 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997005161A1 true WO1997005161A1 (en) | 1997-02-13 |
Family
ID=10778404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/003314 WO1997005161A1 (en) | 1995-07-28 | 1996-07-26 | Boronic acid derivatives |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU6737996A (es) |
CO (1) | CO4750837A1 (es) |
GB (1) | GB9515489D0 (es) |
WO (1) | WO1997005161A1 (es) |
ZA (1) | ZA966396B (es) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045912A1 (en) * | 2001-11-29 | 2003-06-05 | Warner-Lambert Company Llc | Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
KR20030080810A (ko) * | 2002-04-11 | 2003-10-17 | 주식회사 엘지생명과학 | 아미노피리도아릴 그룹을 가진 선택적 트롬빈 억제제 |
EP1396269A1 (en) | 2002-09-09 | 2004-03-10 | Trigen Limited | Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis |
US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
EP2982668A2 (en) | 2002-12-03 | 2016-02-10 | Pharmacyclics LLC | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0471651A2 (en) * | 1990-08-13 | 1992-02-19 | Sandoz Ltd. | Peptide boronic acid derivatives having protease inhibiting activity |
WO1994020526A1 (en) * | 1993-03-03 | 1994-09-15 | Sandoz Ltd. | Peptide boronic acid derivatives having protease inhibiting activity |
WO1995020603A1 (en) * | 1994-01-26 | 1995-08-03 | Sandoz Ltd. | Inhibitors of serine proteases, bearing a chelating group |
-
1995
- 1995-07-28 GB GBGB9515489.4A patent/GB9515489D0/en active Pending
-
1996
- 1996-07-26 AU AU67379/96A patent/AU6737996A/en not_active Abandoned
- 1996-07-26 WO PCT/EP1996/003314 patent/WO1997005161A1/en active Application Filing
- 1996-07-26 CO CO96039770A patent/CO4750837A1/es unknown
- 1996-07-26 ZA ZA9606396A patent/ZA966396B/xx unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0471651A2 (en) * | 1990-08-13 | 1992-02-19 | Sandoz Ltd. | Peptide boronic acid derivatives having protease inhibiting activity |
WO1994020526A1 (en) * | 1993-03-03 | 1994-09-15 | Sandoz Ltd. | Peptide boronic acid derivatives having protease inhibiting activity |
WO1995020603A1 (en) * | 1994-01-26 | 1995-08-03 | Sandoz Ltd. | Inhibitors of serine proteases, bearing a chelating group |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP1744A (en) * | 2001-11-29 | 2007-05-29 | Warner Lambert Co | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade |
KR100712782B1 (ko) * | 2001-11-29 | 2007-05-02 | 워너-램버트 캄파니 엘엘씨 | 응고 캐스케이드에 관여되는 인자 Xa 및 기타 세린프로테아제의 억제제 |
CN1582274B (zh) * | 2001-11-29 | 2011-03-09 | 沃纳-兰伯特公司 | Xa因子以及凝结级联系统中涉及的其他丝氨酸蛋白酶的抑制剂 |
US7407972B2 (en) | 2001-11-29 | 2008-08-05 | Pfizer Inc. | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
US7407974B2 (en) | 2001-11-29 | 2008-08-05 | Pfizer Inc. | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
WO2003045912A1 (en) * | 2001-11-29 | 2003-06-05 | Warner-Lambert Company Llc | Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
KR100688814B1 (ko) * | 2001-11-29 | 2007-03-02 | 워너-램버트 캄파니 엘엘씨 | 응고 캐스케이드에 관여되는 인자 Xa 및 기타 세린프로테아제의 억제제 |
EA007579B1 (ru) * | 2001-11-29 | 2006-12-29 | Уорнер-Ламберт Компани Ллс | ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД |
KR20030080810A (ko) * | 2002-04-11 | 2003-10-17 | 주식회사 엘지생명과학 | 아미노피리도아릴 그룹을 가진 선택적 트롬빈 억제제 |
US7371729B2 (en) | 2002-09-09 | 2008-05-13 | Trigen Limited | Boronic acid salts useful in parenteral formulations |
US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
EP1466917A1 (en) | 2002-09-09 | 2004-10-13 | Trigen Limited | Method for making peptide boronic acids and acids obtainable thereby |
EP1396269A1 (en) | 2002-09-09 | 2004-03-10 | Trigen Limited | Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis |
EP2982668A2 (en) | 2002-12-03 | 2016-02-10 | Pharmacyclics LLC | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders |
Also Published As
Publication number | Publication date |
---|---|
GB9515489D0 (en) | 1995-09-27 |
AU6737996A (en) | 1997-02-26 |
ZA966396B (en) | 1998-01-26 |
CO4750837A1 (es) | 1999-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5750520A (en) | Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives | |
US5607937A (en) | Piperazides of substituted phenylalanine derivatives as thrombin inhibitors | |
US5672582A (en) | Thrombin inhibitors | |
EP0509080B1 (en) | Inhibitors and substrates of thrombin | |
US5371072A (en) | Asp-Pro-Arg α-keto-amide enzyme inhibitors | |
US6420438B1 (en) | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | |
AU670381B2 (en) | Thrombin inhibitors | |
US5798352A (en) | Antithrombotic amidinotetrahydropyridylalanine derivatives | |
NZ298699A (en) | 3-amino-1,2-dihydropyrid-1-yl(and 5-amino-1,6-dihydro-6-oxo(and 5,6-dioxo)pyrimidin-1-yl)-acetyl-argininal derivatives, useful for the treatment of blood coagulation and thrombosis | |
EP0688336B1 (en) | Peptide boronic acid derivatives having protease inhibiting activity | |
US4954519A (en) | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents | |
EP1115390B1 (en) | Hydroxamate-containing cysteine and serine protease inhibitors | |
EP1628971B1 (en) | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
WO1997005161A1 (en) | Boronic acid derivatives | |
EP0922054B1 (en) | Anticoagulant peptidyl-arginine aldehyde derivatives | |
US6239150B1 (en) | Penicillaminamide derivatives | |
WO2001019795A1 (en) | Azacycloalkanone serine protease inhibitors | |
US4490388A (en) | Amidine compound and anticomplement agent comprising same | |
US6063794A (en) | Selective factor Xa inhibitors | |
US5648338A (en) | Inhibitors and substrates of thrombin | |
AU713527B2 (en) | Thrombin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |